BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if BIBF 1120 can increase the number of women with
bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer who do not progress
for at least six months.